Novel lead compounds in pre-clinical development against African sleeping sickness

Domain:

healthcare

Record type:

paper

Creator:

MicIneAliUlr

Publisher:

Roy

Host:

This article reviews the recent progress in drug development against the African sleeping sickness.

Visit

Similar

Molecular epidemiology of African sleeping sicknessIn silico drug re-purposing against African sleeping sickness using GlcNAc-PI de- N -acetylase as an experimental targetHistory of Sleeping Sickness in East AfricaCost-effectiveness of end-game strategies against sleeping sickness across the Democratic Republic of CongoInvestigation of thiazolyl–benzothiophenamides as potential agents for African sleeping sicknessCell Cycle Inhibition To Treat Sleeping Sickness

Molecular epidemiology of African sleeping sickness

SUMMARY Human sleeping sickness in Africa, caused by Trypanosoma brucei spp. raises a number of q

In silico drug re-purposing against African sleeping sickness using GlcNAc-PI de- N -acetylase as an experimental target

History of Sleeping Sickness in East Africa

SUMMARY The history of human sleeping sickness in East Africa is characterized by the appearance of

Cost-effectiveness of end-game strategies against sleeping sickness across the Democratic Republic of Congo

Abstract Background

Investigation of thiazolyl–benzothiophenamides as potential agents for African sleeping sickness

African sleeping sickness is a potentially fatal neglected disease affecting sub-Saharan Africa.

Cell Cycle Inhibition To Treat Sleeping Sickness

ABSTRACT African trypanosomiasis is caused by infection with the protozoan parasite Trypanosoma bru